Analysts expect aTyr Pharma Inc (NASDAQ:LIFE) to post earnings per share of ($0.30) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for aTyr Pharma’s earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.31). aTyr Pharma posted earnings of ($0.43) per share during the same quarter last year, which would indicate a positive year over year growth rate of 30.2%. The firm is scheduled to announce its next earnings report on Tuesday, November 13th.
According to Zacks, analysts expect that aTyr Pharma will report full-year earnings of ($1.29) per share for the current financial year, with EPS estimates ranging from ($1.36) to ($1.21). For the next financial year, analysts expect that the business will report earnings of ($1.21) per share, with EPS estimates ranging from ($1.45) to ($0.97). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow aTyr Pharma.
aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01).
Several analysts have recently issued reports on LIFE shares. Piper Jaffray Companies reiterated an “overweight” rating and set a $3.00 price target on shares of aTyr Pharma in a research note on Monday, May 14th. Citigroup downgraded aTyr Pharma from a “neutral” rating to a “sell” rating in a research note on Monday, May 14th. ValuEngine upgraded aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Zacks Investment Research downgraded aTyr Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th. Finally, BMO Capital Markets decreased their price target on aTyr Pharma from $2.00 to $1.00 and set a “hold” rating for the company in a research note on Wednesday, August 15th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $1.94.
Shares of LIFE traded up $0.02 during trading hours on Wednesday, hitting $0.77. 268,379 shares of the company were exchanged, compared to its average volume of 671,799. The company has a market cap of $22.39 million, a PE ratio of -0.41 and a beta of 2.98. aTyr Pharma has a 52 week low of $0.60 and a 52 week high of $6.50. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.96 and a current ratio of 5.96.
In other aTyr Pharma news, Director Paul Schimmel bought 164,411 shares of the firm’s stock in a transaction that occurred on Thursday, August 30th. The stock was purchased at an average price of $0.74 per share, for a total transaction of $121,664.14. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 25.00% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of LIFE. Deutsche Bank AG acquired a new position in aTyr Pharma in the 4th quarter valued at approximately $199,000. Dimensional Fund Advisors LP raised its holdings in aTyr Pharma by 33.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 114,449 shares of the biotechnology company’s stock valued at $303,000 after acquiring an additional 28,699 shares in the last quarter. Sofinnova Ventures Inc acquired a new position in aTyr Pharma in the 1st quarter valued at approximately $4,945,000. Finally, Renaissance Technologies LLC raised its holdings in aTyr Pharma by 37.6% in the 2nd quarter. Renaissance Technologies LLC now owns 533,861 shares of the biotechnology company’s stock valued at $486,000 after acquiring an additional 145,761 shares in the last quarter. 44.63% of the stock is owned by hedge funds and other institutional investors.
About aTyr Pharma
aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.